Novo Nordisk Announces Significant Price Drops for Popular GLP-1 Medications Mike Hollan Key Takeaways Novo Nordisk will set a $675/month US list price (effective January 1, 2027) for Wegovy, Ozempic, and Rybelsus, targeting affordability for high-deductible and coinsurance designs
Any dose changes should always be made with a licensed healthcare provider
These medications combine the effects of a GLP-1 receptor agonist with an agonist for GIP, another hormone produced by the small intestine
Even as prices come down for GLP-1 weight-loss drugs, much cheaper products marketed as GLP-1 supplements can be alluring to consumers
Lamiophlomis rotata , a Tibetan herb containing iridoid glycosides with GLP-1R agonist activity, blocked formalin-induced hyperalgesia, peripheral nerve injury- and bone cancer-induced mechanical allodynia [41]
GLP-1 medications are dispensed by accredited U.S